Fondaparinux Results in Similar Pregnancy Outcomes with Lower Adverse Reaction Rates Compared to Low Molecular Weight Heparin in Chinese Recurrent Miscarriage Women

• Published in: The Tohoku Journal of Experimental Medicine Vol. 262; no. 2; pp. 125 - 131
• Main Authors: Liu, Chunmiao, Ma, Cui, Hao, Yali
• Format: Journal Article
• Language: English
• Published: Japan Tohoku University Medical Press 06.03.2024
• Subjects: Abortion, Habitual - chemically induced; Abortion, Habitual - drug therapy; Anticoagulants - adverse effects; Birth Weight; China - epidemiology; Female; fondaparinux; Fondaparinux - adverse effects; Heparin, Low-Molecular-Weight - adverse effects; Humans; Infant, Newborn; low molecular weight heparin; Pregnancy; Pregnancy Outcome; pregnancy outcomes; recurrent miscarriage; Retrospective Studies; safety; China; low molecular weight heparin; recurrent miscarriage; pregnancy outcomes; fondaparinux; safety
• ISSN: 0040-8727; 1349-3329
• DOI: 10.1620/tjem.2023.J098

Fondaparinux inhibits thrombin generation by inactivating factor Xa, which has the potential to treat recurrent miscarriage (RM). However, more clinical evidence is required to support its application in Chinese women with RM. This research aimed to compare the live birth rate, gestational weeks at delivery, birth weight, Apgar score of newborns, and adverse reaction rates between fondaparinux and low molecular weight heparin (LMWH) in Chinese women with RM. Totally, 132 women with RM treated with fondaparinux or LMWH were included in this retrospective study. According to the corresponding treatment, women with RM were divided into the fondaparinux cohort (N = 45) and LMWH cohort (N = 87). The live birth rate was 68.9% in the fondaparinux cohort and 56.3% in the LMWH cohort, which was not different between the two cohorts (P = 0.161). Multivariable logistics regression analysis suggested that only previous miscarriage times (≥ 4 times vs. < 4 times) were independently related to a lower possibility of live birth in women with RM (odds ratio = 0.431, P = 0.036). It was also observed that gestational weeks at delivery (38.1 ± 1.4 vs. 37.7 ± 1.7 weeks) (P = 0.258), birth weight (2,923.7 ± 355.0 vs. 2,807.8 ± 334.0 g) (P = 0.144), and Apgar score of newborns (9.8 ± 0.5 vs. 9.6 ± 0.8) (P = 0.175) were not different between the fondaparinux cohort and LMWH cohort. Inspiringly, the total adverse reaction rate was reduced in the fondaparinux cohort vs. the LMWH cohort (20.0% vs. 37.9%) (P = 0.036). Fondaparinux results in similar pregnancy outcomes with lower adverse reaction rates compared to LMWH in Chinese women with RM.